ACAD Stock Analysis: ACADIA Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 4.962m USD | 12M Return: 19.7% | US0042251084 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 40.1M
Qual. Beats: 0
Rev. Trend: 94.0%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ACADIA Pharmaceuticals is a U.S. biopharmaceutical company (NASDAQ: ACAD, mid-cap) headquartered in San Diego, founded in 1993 and formerly known as Receptor Technologies. The company focuses on developing and commercializing treatments for neurological and rare diseases, primarily in North America. Its two approved products are NUPLAZID (pimavanserin) for Parkinsons disease psychosis and DAYBUE (trofinetide, licensed from Neuren Pharmaceuticals) for Rett syndrome.
ACADIAs pipeline spans multiple central nervous system indications, with candidates in Phase 1 and Phase 2 trials targeting Alzheimers disease psychosis, Lewy body dementia psychosis, major depressive disorder, essential tremor, tardive dyskinesia, Huntingtons disease, Rett syndrome, fragile X syndrome, and SYNGAP1 syndrome. The company also has a discovery-stage antisense oligonucleotide program with partner Stoke Therapeutics focused on severe genetic neurodevelopmental diseases of the CNS.
- DAYBUE launch accelerates Rett syndrome revenue growth
- NUPLAZID Parkinson psychosis franchise defends against new entrants
- Phase 2 Alzheimers psychosis data readouts pipeline catalysts
| Net Income: 380.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -6.91 > 1.0 |
| NWC/Revenue: 75.80% < 20% (prev 61.88%; Δ 13.92% < -1%) |
| CFO/TA 0.09 > 3% & CFO 160.3m > Net Income 380.5m |
| Net Debt (-846.1m) to EBITDA (116.1m): -7.29 < 3 |
| Current Ratio: 3.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (172.9m) vs 12m ago 2.47% < -2% |
| Gross Margin: 91.13% > 18% (prev 91.97%; Δ -0.84% > 0.5%) |
| Asset Turnover: 76.72% > 50% (prev 83.14%; Δ -6.42% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.50 (Total Current Assets 1.22b - Total Current Liabilities 361.4m) / Total Assets 1.74b |
| B: -1.02 (Retained Earnings -1.78b / Total Assets 1.74b) |
| C: 0.07 (EBIT TTM 104.1m / Avg Total Assets 1.48b) |
| D: 2.99 (Book Value of Equity 1.31b / Total Liabilities 436.3m) |
| Altman-Z'' = 3.54 = A |
| DSRI: 1.24 (Receivables 166.3m/119.7m, Revenue 1.14b/1.02b) |
| GMI: 1.01 (GM 91.97% / 91.13%) |
| AQI: 1.44 (AQ_t 0.25 / AQ_t-1 0.17) |
| SGI: 1.12 (Revenue 1.14b / 1.02b) |
| TATA: 0.13 (NI 380.5m - CFO 160.3m) / TA 1.74b) |
| Beneish M = -2.46 (Cap -4..+1) = BBB |
As of August 08, 2026, the stock is trading at USD 29.21 with a total of 1,782,652 shares traded. Over the past week, the price has changed by +12.91%, over one month by +11.49%, over three months by +29.48% and over the past year by +19.71%.
Current recommended Stop Loss: 27.00 (which is 7.6% or 2.3 ATR below the current price).
ACADIA Pharmaceuticals has received a consensus analysts rating of 3.95. Therefore, it is recommended to buy ACAD.
- StrongBuy: 7
- Buy: 6
- Hold: 6
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 33 | 13% |
P/E Trailing = 13.0317
P/E Forward = 77.5194
P/S = 4.3582
P/B = 3.5521
P/EG = 50.8642
Revenue TTM = 1.14b USD
EBIT TTM = 104.1m USD
EBITDA TTM = 116.1m USD
Long Term Debt = unknown (none)
Short Term Debt = 11.6m USD (from shortTermDebt, last fiscal year)
Debt = 110.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 50.8m
Net Debt = -846.1m USD (calculated: Debt 110.3m - CCE 956.5m)
Enterprise Value = 4.12b USD (4.96b + Debt 110.3m - CCE 956.5m)
Interest Coverage Ratio = unknown (Ebit TTM 104.1m / Interest Expense TTM 0.0)
EV/FCF = 28.27x (Enterprise Value 4.12b / FCF TTM 145.6m)
FCF Yield = 3.54% (FCF TTM 145.6m / Enterprise Value 4.12b)
FCF Margin = 12.79% (FCF TTM 145.6m / Revenue TTM 1.14b)
Net Margin = 33.42% (Net Income TTM 380.5m / Revenue TTM 1.14b)
Gross Margin = 91.13% ((Revenue TTM 1.14b - Cost of Revenue TTM 101.0m) / Revenue TTM)
Gross Margin QoQ = 90.81% (prev 90.75%)
Tobins Q-Ratio = 2.36 (Enterprise Value 4.12b / Total Assets 1.74b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 110.3m)
Taxrate = 32.22% (15.0m / 46.5m)
NOPAT = 70.6m (EBIT 104.1m * (1 - 32.22%))
Current Ratio = 3.39 (Total Current Assets 1.22b / Total Current Liabilities 361.4m)
Debt / Equity = 0.08 (Debt 110.3m / totalStockholderEquity, last quarter 1.31b)
Debt / EBITDA = -7.29 (Net Debt -846.1m / EBITDA 116.1m)
Debt / FCF = -5.81 (Net Debt -846.1m / FCF TTM 145.6m)
Total Stockholder Equity = 1.17b (last 4 quarters mean from totalStockholderEquity)
RoA = 25.64% (Net Income 380.5m / Total Assets 1.74b)
RoE = 32.39% (Net Income TTM 380.5m / Total Stockholder Equity 1.17b)
RoCE = 7.54% (EBIT 104.1m / Capital Employed (Total Assets 1.74b - Current Liab 361.4m))
RoIC = 5.28% (NOPAT 70.6m / Invested Capital 1.34b)
WACC = 9.06% (E(4.96b)/V(5.07b) * Re(9.26%) + D(110.3m)/V(5.07b) * Rd(0.0%) * (1-Tc(0.32)))
Discount Rate = 9.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.04 | Cagr: 1.64%
[DCF] Terminal Value 70.49% ; FCFF base≈162.2m ; Y1≈142.2m ; Y5≈114.9m
[DCF] Fair Price = 14.50 (EV 1.65b - Net Debt -846.1m = Equity 2.50b / Shares 172.3m; r=9.06% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.53 | # QB: 0
Revenue Correlation: 94.02 | Revenue CAGR: 20.32% | SUE: 1.57 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.12 | Chg30d=-4.84% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=0.39 | Chg30d=+2.04% | Revisions=-38% | GrowthEPS=-53.0% | GrowthRev=+16.8%
EPS next Year (2027-12-31): EPS=0.85 | Chg30d=-3.18% | Revisions=+29% | GrowthEPS=+119.1% | GrowthRev=+13.1%
[Analyst] Revisions Ratio: -6% (up=6, down=7)